title: Regulatory function of a malleable protein matrix as a novel fermented whey product on features defining the metabolic syndrome.
abstract: Previously, we reported that a malleable protein matrix (MPM), composed of whey fermented by a proprietary Lactobacillus kefiranofaciens strain, has immunomodulatory and anti-inflammatory properties. MPM consumption leads to a considerable reduction in the cytokine and chemokine production (tumor necrosis factor-alpha, interleukin-1beta, and interleukin-6), thus lowering chronic inflammation or metaflammation. Inhibition of metaflammation should provide positive impact, particularly in the context of dyslipidemia, insulin resistance, and hypertension. In this study, we investigated whether short-term MPM supplementation ameliorates those features of metabolic syndrome (MetS). The ability of MPM to potentially regulate triglyceride level, cholesterol level, blood glucose level, and hypertension was evaluated in different animal models. MPM lowers triglyceride level by 37% (P < .05) in a poloxamer 407 dyslipidemia-induced rat model. It also reduces total cholesterol by 18% (P < .05) and low-density lipoprotein-cholesterol level by 32% (P < .05) and raises high-density lipoprotein-cholesterol level by 17% (P < .01) in Syrian Golden hamsters fed a high fat/high cholesterol diet for 2 weeks. MPM reestablishes the fasting glucose insulin ratio index to normal levels (P = .07) in this latter model and lowers the plasma glucose level area under the curve (-10%, P = .09) in fructose-fed rats after 2 weeks of treatment. In spontaneously hypertensive rats, MPM-treated animals showed a reduction of SBP by at least 13% (P < .05) for 4 weeks. Results from this study suggest that MPM is a functional ingredient with beneficial effects on lipid metabolism, blood glucose control, and hypertension that might contribute to the management of MetS and thus reducing the risk of cardiovascular diseases.
authors.affiliation: Technologie Biolactis Inc., Laval, Québec, Canada.
authors.forename: J
authors.initials: J
authors.lastname: Beaulieu
authors.forename: E
authors.initials: E
authors.lastname: Millette
authors.forename: E
authors.initials: E
authors.lastname: Trottier
authors.forename: L-P
authors.initials: LP
authors.lastname: Précourt
authors.forename: C
authors.initials: C
authors.lastname: Dupont
authors.forename: P
authors.initials: P
authors.lastname: Lemieux
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000187:drug effects; D002784:Cholesterol / Q000097:blood; D006224:Cricetinae; D004195:Disease Models, Animal; D005260:Female; D005285:Fermentation; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000032:analysis; D007778:Lactobacillus / Q000378:metabolism*; D008297:Male; D008647:Mesocricetus; D024821:Metabolic Syndrome / Q000097:blood / Q000188:drug therapy*; D008894:Milk Proteins / Q000008:administration & dosage* / Q000032:analysis; D011897:Random Allocation; D051381:Rats; D011918:Rats, Inbred SHR; D000067816:Whey Proteins
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D008894:Milk Proteins; D000067816:Whey Proteins; D002784:Cholesterol